Results 121 to 130 of about 1,422 (217)
A phenomap of TTR amyloidosis to aid diagnostic screening
Abstract Cardiac amyloidosis due to transthyretin (ATTR) remains an underdiagnosed cause of cardiomyopathy. As awareness of the disease grows and referrals for ATTR increase, clinicians are likely to encounter more atypical forms of the condition in clinical practice.
Alexios S. Antonopoulos +4 more
wiley +1 more source
Heart failure in two male patients with late‐onset Fabry mutation (IVS4 + 919G > A)
ESC Heart Failure, Volume 12, Issue 2, Page 1508-1513, April 2025.
Xufei Yang +3 more
wiley +1 more source
Abstract Objective This study aimed to evaluate the utility of left atrial volume and function in uraemic patients using four‐dimensional automatic left atrial quantification (4D auto LAQ) technology. Methods Thirty‐four undialysed uraemic patients (U‐ND group), 60 dialysed uraemic patients (U‐D group), and 32 healthy volunteers (N group) were enrolled
Bing Li, Meihua Chen, Xuning Huang
wiley +1 more source
Abstract Aims Amyloid cardiomyopathy is caused by the deposition of light chain (AL) or transthyretin amyloid (ATTR) fibrils, that leads to a restrictive cardiomyopathy, often resulting in heart failure (HF) with preserved or reduced ejection fraction.
Robin Willixhofer +25 more
wiley +1 more source
Abstract Aims Mortality in cardiogenic shock (CS) remains elevated, with the potential for CS causes to impact prognosis and risk stratification. The aim was to investigate in‐hospital prognosis and mortality in CS patients according to aetiology. We also assessed the prognostic accuracy of CardShock and IABP‐SHOCK II scores.
Cosme García‐García +17 more
wiley +1 more source
Abstract Aims SPARCL1 was recently identified as a biomarker of right ventricular (RV) maladaptation in patients with pulmonary hypertension (PH), and N‐terminal pro‐brain natriuretic protein (NT‐proBNP) is an established biomarker of RV failure in PH. The present study investigated whether NT‐proBNP and SPARCL1 concentrations are associated with load ...
Oliver Dörr +15 more
wiley +1 more source
Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad +9 more
wiley +1 more source
Paroxysmal slow waves mark ictal networks
Abstract Objective Epilepsy diagnosis and treatment monitoring are hindered by the episodic, heterogeneous expression of seizures and by normal‐appearing scalp electroencephalography (EEG) in many patients. We previously described paroxysmal slow‐wave events (PSWEs), brief epochs of broadband slowing detectable on EEG in people with epilepsy.
Florent J. M. Boyer‐Aymé +13 more
wiley +1 more source
Abstract Background Tissue Doppler imaging (TDI) may improve the assessment of myocardial function in neonatal foals. Objectives To document the feasibility of left ventricular pulsed wave (PW) TDI, inter‐ and intra‐observer variability and wave pattern over the first 5 days of life. Study Design Prospective observational study.
Fernanda Timbó D'el Rey Dantas +8 more
wiley +1 more source
Peptides on Tap: Automated Flow Synthesis With Standard HPLC
A standard analytical HPLC system is repurposed into a fully automated, flow‐based peptide synthesis platform. By leveraging the autosampler for automated reagent injections into a resin‐packed guard column, this highly accessible method enables rapid, temperature‐controlled coupling with real‐time UV monitoring, producing high‐purity peptides and ...
Patrick Romanens +5 more
wiley +1 more source

